Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
APL receives final approval for Ramipril from USFDA
Aurobindo Pharma Limited (APL) received final approval from the USFDA to manufacture
and market Ramipril capsules (1.25mg, 2.5mg, 5mg and 10mg). Ramipril is the generic
equivalent of Altace capsules that are indicated for the treatment of hypertension and fall
under the CVS therapeutic segment. The product has a market size of ~US$95 million as
on September 2010 according to IMS data. APL expects to launch the product soon. The
stock is currently trading at 11.4x and 9.2x its FY12E and FY13E earnings respectively. We
maintain a Buy on the stock with a target price of `278.
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
APL receives final approval for Ramipril from USFDA
Aurobindo Pharma Limited (APL) received final approval from the USFDA to manufacture
and market Ramipril capsules (1.25mg, 2.5mg, 5mg and 10mg). Ramipril is the generic
equivalent of Altace capsules that are indicated for the treatment of hypertension and fall
under the CVS therapeutic segment. The product has a market size of ~US$95 million as
on September 2010 according to IMS data. APL expects to launch the product soon. The
stock is currently trading at 11.4x and 9.2x its FY12E and FY13E earnings respectively. We
maintain a Buy on the stock with a target price of `278.
No comments:
Post a Comment